To include your compound in the COVID-19 Resource Center, submit it here.

ICER assesses cost-effectiveness of PARP inhibitors

In an evidence report released Wednesday, the Institute for Clinical and Economic Review said most prices of PARP inhibitors are too high to align with estimated benefit in designated populations, and found insufficient evidence to compare PARP inhibitors across key ovarian cancer indications.

The institute

Read the full 449 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE